Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine
Open Access
- 1 November 1998
- journal article
- clinical trial
- Published by Springer Nature in Molecular Psychiatry
- Vol. 3 (6) , 508-511
Abstract
Depression with psychotic features has been shown to respond to selective serotonin reuptake inhibitors (SSRIs). The serotonin transporter (5-HTT) is a prime target for SSRIs. A functional polymorphism within the promoter region of the 5-HTT gene, leading to different transcriptional efficiency, was recently reported. We tested the hypothesis that allelic variation of the 5-HTT promoter could be related to the antidepressant response to fluvoxamine and/or augmentation with pindolol (a serotonin autoreceptors antagonist) which has been suggested as an augmentation therapy for nonresponders. One hundred and two inpatients with major depression with psychotic features were randomly assigned to treatment with a fixed dose of fluvoxamine and either placebo or pindolol for 6 weeks. Depression severity was assessed once a week using the Hamilton Depression Rating Scale. Allelic variation in each subject was determined using a PCR-based method. Data were analyzed with a three-way repeated measures analysis of variance. Both homozygotes for the long variant (l/l) of the 5-HTT promoter and heterozygotes (l/s) showed a better response to fluvoxamine than homozygotes for the short variant (s/s). In the group treated with fluvoxamine plus pindolol all the genotypes acted like l/l treated with fluvoxamine alone. Fluvoxamine efficacy in delusional depression seems to be related to allelic variation within the promoter of the 5-HTT gene. Even though other factors may be implicated, genotyping at 5-HTT promoter may represent a promising tool to individualize the pharmacological treatment of depression.Keywords
This publication has 16 references indexed in Scilit:
- Preferential Potentiation of the Effects of Serotonin Uptake Inhibitors by 5‐HT1A Receptor Antagonists in the Dorsal Raphe Pathway: Role of Somatodendritic AutoreceptorsJournal of Neurochemistry, 1997
- Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatmentThe Lancet, 1997
- Selective Activation of Postsynaptic 5-HT1A Receptors Induces Rapid Antidepressant ResponseNeuropsychopharmacology, 1997
- Oxidative stress affects the selective ion permeability of voltage-sensitive Ca2+ channels in cultured retinal cellsNeuroscience Research, 1997
- Expression of Serotonin Transporter mRNA in Human Brainstem Raphe NucleiNeuropsychopharmacology, 1996
- Allelic Variation of Human Serotonin Transporter Gene ExpressionJournal of Neurochemistry, 1996
- Pindolol, 5-Hydroxytryptamine, and Antidepressant AugmentationArchives of General Psychiatry, 1995
- Dopamine transporter mediated release of dopamine: Role of chlorideJournal of Neuroscience Research, 1994
- Neurotransmitter‐mediated signaling between axons and glial cellsGlia, 1994
- Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization.Proceedings of the National Academy of Sciences, 1993